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Supplementary Methods 
 
Phosphohistidine dot blot 
Recombinant PGAM and NME1 proteins (Clubbs-Couldron et al., in press) were histidine-phosphorylated in 
vitro by incubation with 1 mM 2,3-diphosphoglycerate (DPG, Sigma) or 1 mM adenosine triphosphate (ATP, 
Sigma), respectively, for 5 min at room temperature. Myoglobin was phosphorylated with potassium 
phosphoramidate as described in Methods. All proteins (phosphorylated and unphosphorylated) were then 
dotted onto nitrocellulose membrane (GE Healthcare) and allowed to dry completely. Membranes were 
blocked with 5% (w/v) non-fat dry milk (Marvel) in TBS with 0.1% (v/v) Tween20, and incubated overnight 
at 4°C with either N1-phosphohistidine antibody (Merck MABS1341, clone SC50-3), N3-phosphohistidine 
antibody (Merck MABS1351, clone SC39-6) or no antibody (Fuhs et al. 2015). The next day, all membranes 
were incubated with an HRP-conjugated anti-mouse secondary antibody (Cell Signaling Technology, #7076) 
and imaged on a ChemiDoc MP Imaging System (BioRad). 
 
Phosphohistidine peptide stability test 
Myoglobin peptides (1 nmol) were diluted to 100 μL in either 0.5% TFA (pH 1) or 20 mM ammonium 
acetate (pH 4, pH 6 or pH 9). Samples were incubated at 25 °C with shaking at 600 rpm. At timed intervals 
(15 minutes, 30 minutes, 1 hour and 2 hours) 5 μL of sample was removed, neutralised (e.g. by addition of 
5 μL ammonium hydroxide to samples at pH 1) and diluted to 500 fmol/μL with H2O:ACN (97:3) for LC-
MS/MS analysis with the Bruker AmaZon instrument. This experiment was performed in triplicate for each 
pH. 
 
Calcium phosphate precipitation 
Myoglobin and α/β-casein peptides (50 pmol) were diluted to 50 μL in H2O. Sodium phosphate (2 µL of 0.5 
M) and ammonia water (2 µL of 2 M) were added, and the pH of the resulting solution determined to be 
approximately pH 10 using universal indicator paper. Phosphopeptides were enriched using calcium 
phosphoate precipitation according to the method described in (Zhang et al 2007). CaCl2 (2 µL of 2 M) was 
added and the sample mixed using a vortex mixer for 5 minutes, followed by centrifugation at 13,000 rpm 
for 15 minutes. The resulting supernatant was transferred to a clean low bind sample tube. CaCl2 (100 µL of 
80 mM) was added to the precipitate which was briefly mixed and then centrifuged as before. The resulting 
supernatant was combined with that of the previous step, and the wash step repeated with a further 100 
µL of 80 mM CaCl2, again combining the supernatant fractions. The precipitate was resolubilised in 10 µL of 
either 5% (v/v) or 0.1% (v/v) TFA and immediately transferred to a C18 StageTip for sample desalting. 
 
Hydroxyapatite enrichment  
Phosphopeptides were enriched according using a method adapted from (Mamone et al 2010). 
Hydroxyapatite (HAP) resin (5 mg; Bio-Gel HTP, Bio-Rad) was suspended in 200 µL loading buffer (20 mM 
Tris-HCl (pH 7.2)) and added to a Pierce spin column (Thermo Scientific). This was centrifuged at 300 g for 1 
minute to remove the buffer and washed with a further 50 µL loading buffer, and again centrifuged. 
Centrifugation of the spin column at 3000 g for 1 minute was used to collect all subsequent fractions. 
Tryptic peptides of α- and β-casein and histidine-phosphorylated myoglobin (40 pmol) in 50 µL of loading 
buffer was added to the resin in the spin column and incubated with gentle rotation at room temperature 
for 30-45 minutes. The flow-through was collected and the resin washed twice with 200 µL of loading 
buffer, which was also collected. The resin was then washed twice with 200 µL of wash buffer (20 mM Tris-
HCl (pH 7.2), 20% (v/v) ACN) which was again collected. To recover the phosphopeptides, the resin was 
incubated twice with 100 µL elution buffer (1.0 M K2HPO4 at pH 7.8, pH 7.0 or pH 6.8), rotating for 15 
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minutes at room temperature each time, before collecting and combining the eluent fractions. All fractions 
were dried by vacuum centrifugation and reconstituted in H2O:ACN (97:3) for LC-MS/MS analysis with the 
Bruker AmaZon instrument. As an alternative approach tryptic peptides of α- and β-casein and histidine-
phosphorylated myoglobin (20 pmol) in 50 µL of loading buffer was added to HAP resin and washed as 
described above. The resin was then washed with H2O (100 μL) and incubated with 500 mM hydroxylamine 
(50 μL) for 1 hour at 37 °C with shaking. This was collected and all eluates were dried and analysed as 
previously described. 
 
Intact protein MS analysis 
Analysis of intact phosphorylated myoglobin was conducted using a Waters Synapt G2-Si instrument. 
Phosphorylated myoglobin (5 μM in 20 mM ammonium acetate:ACN 50:50) was analysed using borosilicate 
emitters (Thermo ES 387). Spraying voltage was adjusted to 1.5 kV, sampling cone was 50 V.  The time-of-
flight mass analyser was set to Resolution Mode. Data was processed using Mass Lynx V4.1, with 
deconvolution performed using MaxEnt 1.  
 
Estimation of false localisation rate (FLR) 
To address a potential concern that consideration of multiple phosphorylated residues was compromising 
statistical confidence in phosphosite identification, we used the same search parameters to evaluate the 
prevalence of a theoretical pAla residue, by substituting variable modification of pCys for pAla.  It was first 
verified that the “pAla” search results produced almost identical counts of PSMs at 5% FDR. We analysed 
the results from the ptmRS scoring of pAla at different thresholds to estimate the FLR amongst the 
different residues in the main search. Identifications of pAla are known to be chemically impossible, so we 
use apparent pAla counts (at different ptmRS thresholds) to estimate the rate at which the workflow 
randomly assigns a phosphosite to a given amino acid. The pAla counts thus need to be normalised per 
amino acid considered, taking into account the relative frequencies of each amino acid i.e. a rare amino 
acid would have fewer chances of being randomly (and wrongly) assigned a phosphosite than a common 
amino acid. 
To normalise pAla counts at a given threshold, we first calculated the count of each amino acid within the 
set of redundant PSMs supporting phosphopeptides only. The rationale for normalising first by amino acid 
counts within the redundant phosphopeptide set considers two factors. First, only identified 
phosphopeptides progress to ptmRS scoring, so it is less relevant what amino acid counts are present in the 
search database or in peptides without phosphosites. Particular amino acids are seen more or less than 
would be expected by chance in the set of phosphopeptides e.g. Glu residues appear only 10% more than 
Ala in the search database, but more than 2X higher in the PSMs supporting phosphopeptides, and thus FLR 
estimates need to reflect this fact. Second, normalisation first in the redundant (non-unique) set is likely to 
be more conservative, if there are particular amino acids enriched on (abundant) peptides supported by 
many PSMs, would give more opportunities for ptmRS to assign false localisations to these amino acids.  
We calculated the count of non-unique pAla sites at each given ptmRS threshold NU_SpAla, and the count of 
all Ala residues NU_PSMsAla in the non-unique PSM set. We then calculated the frequency of any amino acid 
being randomly assigned a phosphorylation site: AA_RF = NU_SpAla / NU_PSMsAla. To estimate the non-
unique false localisation site count per amino acid, we used the following formula: NU_FLSx = AA_RF * 
NU_PSMsx (where x = C, D, E, H, K non C-terminal, R non C-terminal, S, T or Y). As noted in the text, we 
observe unexpectedly high counts of C-terminal sites on Lys and Arg, so for FLR calculation, only non C-
terminal sites are considered. 
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We next calculated the FLR within the unique set of sites by estimating a single collapse factor (CF) to 
model the rate at which random false positive sites collapse from the non-unique counts to unique site 
counts, as follows CF = U_SpAla / NU_SpAla. For each amino acid, the final estimate of the unique false 
localisation site Count U_FLSx = NU_FLSx * CF and the final unique false localisation rate FLRx = U_FLSx / U_Sx 
(where U_Sx is the count of unique sites per amino acid). The rationale for using a single collapse factor for 
all residues is that it would be expected that false localisations would collapse from the non-unique to the 
unique-level at a different rate i.e. true positive sites would be predicted to be, on average, supported by 
more PSMs than random, incorrect sites. Thus we use the CF estimate from pAla only to estimate the 
conversion from non-unique to unique false positive sites. For each amino acid, the estimate of true 
positive sites is TPSx = U_Sx – U_FLSx. See Appendix Table S5 for a worked example at ptmRS > 0.90, where 
NU_PSMsAla = 51205; NU_SpAla = 263, therefore AA_RF = 0.005136. 
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Appendix Figures 
 
 
Appendix Figure S1. Stability profiles of pHis-containing tryptic peptides.  
Extracted ion chromatograms were used to determine the normalised relative signal intensity of the pHis-
containing tryptic myoglobin peptides LFTGH*PETLEK at m/z 676.3 and VEADIAGH*GQEVLIR at m/z 843.9 
as a function of (A) pH at pH 9, pH 6, pH 4 and pH 1, or (B) temperature at either 80 °C or 95 °C at pH 7.2. 
Signal intensity was normalised against a non-histidine-containing peptide and presented as a percentage 
compared to the amount at time t=0. Phosphohistidine-containing peptides exhibit a much reduced 
stability at pH 1 compared to pH 4, pH 6 and pH 9. Data is representative of all myoglobin pHis-containing 
peptides. 
 
A 
B 
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Appendix Figure S2. pHis-containing peptides undergo hydrolysis during TiO2 enrichment.  
Overlay of extracted ion chromatograms at m/z 803.9 for the non-phosphorylated counterpart of the pHis-
containing myoglobin peptide VEADIAGHGQEVLIR before (load; red) and after (recovery; green) TiO2 
phosphopeptide enrichment under standard acidic conditions.  Data is representative of multiple pHis 
peptides and multiple repeats. >100% recovery of the non-phosphorylated peptide indicates neutral loss of 
phosphate from the corresponding pHis-containing peptide. 
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Appendix Figure S3. Numbers of non-phosphorylated and phosphorylated peptides identified per pooled 
SAX fraction (5% FDR), according to phosphorylated amino acid (ptmRS ≥0.90).  
Below threshold refers to phosphopeptides with ptmRS < 0.90. Phosphopeptide diversity is highlighted in the 
zoomed region in the right panel.   
Hardman et al., 2019  Appendix: The expanding human phosphoproteome 
Page 9 of 32 
 
 
 
Appendix Figure S4. ptmRS distribution (probability) of peptide spectrum matches (PSMs) according to 
phosphorylated residue.  
The number of PSMs assigned as a being phosphorylated on Ala, Asp, Glu, His, Lys (localised either to the 
peptide C-terminus (Kc), or internally (Knon-c)), Arg (Rc or Rnon-C), Ser, Thr or Tyr are binned according to 
probability of site localisation (ptmRS) score (0.4 to 1.0). Score distribution for pAla is broadly similar to that 
observed for other (non-C-terminally assigned) phosphorylated residues. 
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Appendix Figure S5. pAla computed FLR estimate for each type of canonical and non-canonical 
phosphorylated residue at ptmRS values ≥0.99, ≥0.90 or ≥0.75 at a 1% PSM FDR. pLys* and pArg* 
represent those phosphorylation sites on Lys or Arg (respectively) that are not localised to the peptide C-
terminus. 
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Appendix Figure S6. Example tandem mass spectra for pHis-containing peptides  
HCD product ion spectra of (top) 4+ ion at m/z 966.42: RTSDPSAAVNpHVSSTTSLGENYEDDDLVNSDEVMK 
from Alastin-2 (Q8NHH9); (middle) 3+ ion at m/z 872.71: IEDSEPpHIPLIDDTDAEDDAPTK from Plasma 
membrane calcium-transporting ATPase 1 (P20020); (bottom) 3+ ion at m/z 1131.47: 
TAMSTPpHVAEPAENEQDEQDENGAEASADLR from Moesin (P26038). 
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A 
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Appendix Figure S7. Spectral comparison of HCD tandem mass spectra of synthetic chemically 
phosphorylated pHis peptides (bottom) with the analogous pHis-containing spectra from the high-
throughput UPAX data (top).  (A) doubly charged ion at m/z 753.65 pHNSESESVPSSMFILEDDR from RICTOR 
(Q6R327); (B) doubly charged ion at m/z 819.36 SESPDpHMVSQYQQALEEIER from MORC3 (Q14149); (C) 
triply charged ion at m/z 721.31 from SVIL (O95425). All spectra were manually annotated with the aid of 
xiSPEC (Kolbowski et al 2018). Unlabelled light red peaks are neutral loss-assigned product ions 
 
 
  
C 
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Appendix Figure S8. Motif analysis for pHis-containing peptides. The amino acid sequences surrounding 
confidently localised sites of pHis (ptmRS ≥ 0.99) were analysed for sequence enrichment using Motif-X 
(Chou & Schwartz, 2011; Schwartz & Gygi, 2005). Depicted are the sequences of the enriched motifs.  
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Appendix Figure S9. EThcD product ion mass spectrum of singly phosphorylated DHSPTPSVFNSDEER 
from FIP1L1. FIP1L1 protein was overexpressed and purified from HEK293T cells, subjected to tryptic 
digestion and analysed by LC-MS/MS. A precursor ion of m/z 898.8594 corresponding to the doubly 
charged form of the singly phosphorylated peptide DHSPTPSVFNSDEER was isolated and subjected to 
EThcD for MS2 analysis in the ion trap. Fragment ions were manually assigned using xiSPEC (Kolbowski 
et al 2018). Site determining ions indicating phosphorylation of either His at position 2 (blue) or Ser at 
position 3 (green) are annotated, suggesting co-isolation of phosphopeptide isomers and generation of 
a chimeric spectrum. Common fragment ions are shown in red.  
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Appendix Figure S10. Example tandem mass spectra for pAsp-containing peptides. HCD product ion 
spectra of (top) 4+ ion at m/z 858.36: AENDVDNELLpDYEDDEVETAAGGDGAEAPAKK from Spliceosome RNA 
helicase DDX39B (Q13838); (middle) 3+ ion at m/z 858.36: GHDLSPLASDILTNTSGSMpDEGDDYLPATTPALEK 
from Microtubule-associated protein 2 (P11137); (bottom) 3+ ion at m/z 799.66 
MESHSEDEpDLAGAVGGLGWNSR: from Transcriptional regulator HEXIM2 (Q96MH2). 
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Appendix Figure S11. Motif analysis for pAsp-containing peptides. The amino acid sequences surrounding 
confidently localised sites of pAsp (ptmRS ≥ 0.99) were analysed for sequence enrichment using Motif-X 
(Chou & Schwartz, 2011; Schwartz & Gygi, 2005). Depicted are the sequences of the enriched motifs. 
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Appendix Figure S12. Example tandem mass spectra for pGlu-containing peptides. HCD product ion 
spectra of (top) 2+ ion at m/z 1015.94: GDSpETDLEALFNAVMNPK from Transcriptional coactivator YAP1 
(P46937); (middle) 3+ ion at m/z 1139.80: QQAHYDAMDNDIVQGApEDQGIQGEEGAYER from Golgi integral 
membrane protein 4 (O00461); (bottom) 2+ ion at m/z 1160.48: AFVEDSEDpEDGAGEGGSSLLQK from 
Protein KRI1 homolog (Q8N9T8). 
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Appendix Figure S13. Motif analysis for pGlu-containing peptides. The amino acid sequences surrounding 
confidently localised sites of pGlu (ptmRS ≥ 0.99) were analysed for sequence enrichment using Motif-X 
(Chou & Schwartz, 2011; Schwartz & Gygi, 2005). Depicted are the sequences of the enriched motifs. 
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Appendix Figure S14. Example tandem mass spectra for pLys-containing peptides. HCD product ion 
spectra of (top) 3+ ion at m/z 1128.87: ALpKVLDNYLTSPLPEEVDETSAEDEGVSQR from Chloride intracellular 
channel protein 1 (O00299); (middle) 3+ ion at m/z 690.30: TTpKTPEDGDYSYEIIEK from Microtubule-
associated protein 1B (P46821); (top) 3+ ion at m/z 775.07: VVKPpKSPEPEATLTFPFLDK from LIM and 
calponin homology domains-containing protein 1 (Q9UPQ0).  
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Appendix Figure S15. Motif analysis for pLys-containing peptides. The amino acid sequences surrounding 
confidently localised sites of pLys (ptmRS ≥ 0.99) not located at the extreme peptide C-terminal residue 
were analysed for sequence enrichment using Motif-X (Chou & Schwartz, 2011; Schwartz & Gygi, 2005). 
Depicted are the sequences of the enriched motifs. 
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Appendix Figure S16. Example tandem mass spectra for pArg-containing peptides. HCD product ion 
spectra of (top) 3+ ion at m/z 864.35: pRVSVCAETYNPDEEEEDTDPR from cAMP-dependent protein kinase 
type II-alpha regulatory subunit (P13861); (middle) 3+ ion at m/z 671.62: TTpRTPEEGGYSYDISEK from 
Microtubule-associated protein 1B (P46821); (bottom) 3+ ion at m/z 1125.60: 
QATKDAGVIAGLNVLpRIINEPTAAAIAYGLDR from Heat shock 70 kDa protein 1A (P0DMV8).  
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Appendix Figure S17. Motif analysis for pArg-containing peptides. The amino acid sequences surrounding 
confidently localised sites of pArg (ptmRS ≥ 0.99) not located at the extreme peptide C-terminal residue 
were analysed for sequence enrichment using Motif-X (Chou & Schwartz, 2011; Schwartz & Gygi, 2005). 
Depicted are the sequences of the enriched motifs. 
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Appendix Figure S18. Motif analysis for pCys-containing peptides. The amino acid sequences surrounding 
confidently localised sites of pCys (ptmRS ≥ 0.99) were analysed for sequence enrichment using Motif-X 
(Chou & Schwartz, 2011; Schwartz & Gygi, 2005). Depicted are the sequences of the enriched motifs. 
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Appendix Tables 
 
Sequence Site m/z Charge 
VEADIAGHGQEVLIR His25 843.9 2+ 
LFTGHPETLEK His37 676.3 2+ 
HGTVVLTALGGILK His65 729.9 2+ 
GHHEAELKPLAQSHATK His81 645.3 3+ 
GHHEAELKPLAQSHATK His82 645.3 3+ 
GHHEAELKPLAQSHATK His94 645.3 3+ 
YLEFISDAIIHVLHSK His114 655.6 3+ 
 
Appendix Table S1. Phosphohistidine-containing tryptic peptides from myoglobin. Histidine 
phosphorylated myoglobin was subjected to tryptic digestion and analysed by LC-MS/MS analysis with CID 
or ETD. Phosphosite localization (shown as underlined residue) was confirmed by manual annotation of 
spectra. 
 
 
 
 Binding Wash Steps Elution Steps 
A 
65 % MeCN, 2 % TFA, 
saturated with glutamic acid, 
pH 2 
1. 65 % MeCN, 0.5 % TFA 
2. 65 % MeCN, 0.1 % TFA 
1. 300 mM NH3, 50 % MeCN 
2. 500 mM NH3, 60 % MeCN 
B 
65  mM  NH4OAc, 5 % MeCN, 
pH 7.5 
1. 65 % MeCN, 0.5 % TFA 
2. 65 % MeCN, 0.1 % TFA 
1. 300 mM NH3, 50 % MeCN 
2. 500 mM NH3, 60 % MeCN 
C 
3 M lactic acid, 60 % MeCN, 
12.5 % AcOH,  pH 4 
1. 2 M lactic acid, 75 % MeCN, 2 % 
TFA 
2. 2 M lactic acid, 75 % MeCN, 10 % 
AcOH, pH 4 
3. 80 % MeCN, 10% AcOH 
1 % NH3, 30 mM (NH4)3PO4 
 
Appendix Table S2. Conditions evaluated for TiO2 enrichment of pHis (and other) phosphopeptides. 
Binding, sequential washing and sequential elution buffers for each of the three conditions (A, B and C) 
used to assess suitability of TiO2 enrichment specifically for pHis-containing peptides are detailed. Different 
wash and elution solutions were evaluated for each of the three binding conditions. All % are (v/v). 
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% Binding pHis 
peptides 
% Elution pHis 
peptides 
% Recovery non-phosphorylated His 
peptides  
A 95 - 100 % 0 % 54 - 133 % 
B 98 - 100 % 0 % 7  - 164 % 
C 96 - 100 % 0 % 18 - 109 % 
 
 
Appendix Table S3. Enrichment of pHis peptides by TiO2 fails due to acid-induced hydrolysis of pHis. 
Amount of non-phosphorylated histidine-containing peptides recovered after TiO2 enrichment is greater 
than in the original start material. Range of values for binding and elution/recovery represent analysis from 
multiple pHis peptides for 2 replicate experiments. Conditions A, B and C for enrichment are detailed in 
Table S2. 
 
 
 
Bound pHis- 
containing peptides 
Elution pH Eluted pHis-  
containing peptides 
Total recovery of all 
His-containing peptides 
83 - 96 % pH 7.8 0 % 4 - 18 % 
83 - 96 % pH 7.0 0 % 2 - 37 % 
83 - 100 % pH 6.0 0 % 1 - 35 % 
 
 
Appendix Table S4. Recovery of pHis peptides following hydroxyapatite chromatography. Recovery of all 
peptides following hydroxyapatite chromatography was poor, irrespective of elution pH; range of values 
represents recovery of phosphohistidine-containing peptides across at least 2 replicate experiments.  
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ptmRS ≥ 0.75 pSer pThr pTyr pHis pAsp pGlu pLys pArg pCys pAla 
pAla FLR 21% 35% 41% 51% 63% 79% 54% 28% 51% 100% 
siRNA NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 
Total pX peptides 6678 5865 932 827 222 177 175 154 869 742 977 745 182 (433) 169 (411) 209 (294) 194(273) 74 52 356 283 
Total pX peptides 12543 1759 399 329 1611 1722 351 (844) 403 (567) 126 639 
Unique pX sites 2653 2432 567 506 154 116 139 127 618 556 694 559 151 (358) 155 (354) 160 (240) 147 (220) 63 48 251 218 
Unique pX sites 3636 895 236 225 980 1068 268 (626) 278 (419) 103 404 
                     ptmRS ≥ 0.90 pSer pThr pTyr pHis pAsp pGlu pLys pArg pCys pAla 
pAla FLR 13% 26% 28% 36% 61% 79% 41% 23% 38% 100% 
siRNA NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 
Total pX peptides 3961 3448 539 489 119 96 90 79 311 278 343 268 89 (269) 72 (244) 100 (149) 91 (133) 43 27 158 105 
Total pX peptides 7409 1028 215 163 589 611 161 (513) 191 (282) 70 263 
Unique pX sites 1672 1559 313 280 85 69 78 67 242 231 268 219 80 (232) 73 (221) 76 (122) 74 (115) 33 26 106 82 
Unique pX sites 2317 489 138 129 410 427 140 (406) 139 (220) 55 162 
                     ptmRS ≥ 0.99 pSer pThr pTyr pHis pAsp pGlu pLys pArg pCys pAla 
pAla FLR 6% 14% 17% 28% 57% 69% 29% 15% 24% 100% 
siRNA NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 
Total pX peptides 1706 1459 233 233 46 37 21 24 84 61 84 69 23 (123) 23 (109) 34 (62) 32 (54) 15 10 46 20 
Total pX peptides 3165 456 83 45 145 153 46 (232) 66 (116) 25 66 
Unique pX sites 826 733 130 124 31 26 18 21 64 53 68 55 25 (111) 23 (100) 27 (54) 23 (44) 12 10 26 15 
Unique pX sites 1105 210 51 37 99 112 45 (191) 47 (91) 20 37 
 
Appendix Table S5. Total number of phosphopeptides and unique sites identified (5% PSM FDR) for each phosphorylated residue and the hypothetical pAla 
residue, according to site localisation confidence (ptmRS score). Numbers are depicted for all replicate samples treated with either non-targeting (NT) siRNA, 
PHPT1 siRNA, or the combined data from all 6 samples. For pLys and pArg, the number in parentheses is the total number of identified sites/peptides including 
those localised to the peptide C-terminus; outside of parentheses are the non-C-terminal mapped pLys or pArg sites. pAla estimated false localisation rate (FLR) for 
each residue (non-C-terminal Lys/Arg) at each ptmRS value is also presented.  
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Total % at 
each ptmRS 
≥0.99 ≥0.90 ≥0.75 
 UPAX TiO2 UPAX TiO2 UPAX TiO2 
Ser 58.28% 91.93% 51.07% 89.91% 44.97% 87.55% 
Thr 11.08% 5.59% 10.78% 6.05% 11.07% 7.21% 
Tyr 2.69% 1.24% 3.06% 1.15% 2.92% 0.87% 
His 1.95% 0.00% 2.84% 0.29% 2.78% 0.22% 
Asp 5.22% 0.00% 9.04% 0.29% 12.12% 0.87% 
Glu 5.91% 0.00% 9.41% 1.44% 13.21% 1.97% 
Lys 10.07% 0.62% 8.95% 0.29% 7.74% 0.87% 
Arg 4.80% 0.62% 4.85% 0.58% 5.18% 0.44% 
Canonical pX 72.0% 98.8% 64.9% 97.1% 59.0% 95.6% 
Non-canonical 
pX 
28.0% 1.2% 35.1% 2.9% 41.0% 4.4% 
 
 
Appendix Table S6. Proportion of phosphorylated residues identified using either UPAX or with a 
standard TiO2-based phosphopeptide enrichment workflow. All data were acquired using the same LC-
MS/MS acquisition and data interrogation parameters as described in methods. 
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ptmRS ≥ 0.75 pSer pThr pTyr pHis pAsp pGlu pLys pArg pCys pAla 
pAla FLR 17% 37% 45% 58% 54% 72% 65% 34% 81% 100% 
siRNA NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 
Total pX peptides 6073 5378 725 648 166 129 120 97 713 617 783 598 116 (244) 105 (116) 138 (183) 130 (165) 37 25 272 230 
Total pX peptides 11451 1373 295 217 1330 1381 221 (465) 268 (348) 62 502 
Unique pX sites 2331 2141 386 351 103 75 90 78 490 453 531 422 93 (193) 90 (177) 98 (140) 85 (117) 30 21 174 168 
Unique pX sites 3099 586 147 134 779 795 150 (310) 160 (227) 44 284 
                     
ptmRS ≥ 0.90 pSer pThr pTyr pHis pAsp pGlu pLys pArg pCys pAla 
pAla FLR 10% 25% 31% 42% 50% 76% 51% 30% 58% 100% 
siRNA NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 
Total pX peptides 3634 3173 419 385 83 64 56 35 247 217 247 195 52 (133) 39 (107) 59 (85) 51 (66) 21 13 122 86 
Total pX peptides 6807 804 146 91 464 442 91 (240) 110 (151) 34 208 
Unique pX sites 1489 1393 218 193 50 42 47 33 189 178 179 149 46 (112) 37 (92) 39 (64) 35 (49) 15 11 70 64 
Unique pX sites 2005 319 79 70 316 282 72 (181) 67 (103) 23 111 
                     
                     
ptmRS ≥ 0.99 pSer pThr pTyr pHis pAsp pGlu pLys pArg pCys pAla 
pAla FLR 4% 12% 18% 40% 50% 76% 41% 27% 45% 100% 
siRNA NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 NT PHPT1 
Total pX peptides 1564 1359 181 174 32 23 10 7 55 44 47 43 9 (46) 10 (39) 14 (26) 16 (24) 7 4 37 16 
Total pX peptides 2923 355 55 17 99 90 19 (85) 30 (50) 11 53 
Unique pX sites 733 670 88 80 18 14 9 6 41 36 33 33 9 (41) 10 (36) 9 (21) 7 (14) 5 3 16 11 
Unique pX sites 970 132 28 15 64 58 18 (73) 15 (32) 6 23 
 
Appendix Table S7. Total number of phosphopeptides and unique sites identified (1% PSM FDR) for each phosphorylated residue and the hypothetical pAla 
residue, according to site localisation confidence (ptmRS score). Numbers are depicted for all replicate samples treated with either non-targeting (NT) siRNA, 
PHPT1 siRNA, or the combined data from all 6 samples. For pLys and pArg, the number in parentheses is the total number of identified sites/peptides including 
those localised to the peptide C-terminus; outside of parentheses are the non-C-terminal mapped pLys or pArg sites. pAla estimated false localisation rate (FLR) for 
each residue (non-C-terminal Lys/Arg) at each ptmRS value is also presented.  
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pAla decoy estimated pX specific FLR: worked example for ptmRS ≥ 0.90 
NU_PSMsAla  51205 
NU_SpAla 263 
AA_RF  0.005136 
  
Residue NU_PSMsx  NU_FLSx  U_Sx
 CF U_FLSx  FLRx TPSx 
A 51205 263 162 0.616 162 1.00 101 
C 6618 34 55   21 0.38 34 
D 78691 404 410   249 0.61 161 
E 106921 549 427   338 0.79 89 
H 14530 75 129   46 0.36 83 
K internal 18176 93 140   58 0.41 82 
R internal 10023 51 139   32 0.23 107 
S 97141 499 2317   307 0.13 2010 
T 40045 206 489   127 0.26 362 
Y 12288 63 138   39 0.28 99 
 
Appendix Table S8. Worked example demonstrating how False Localisation Rate (FLR) is estimated at 
ptmRS ≥ 0.90 based on the number of pAla ‘identifications’.  
NU_PSMsx = Counts of each amino acid in the non-unique (redundant) set of PSMs for phosphopeptides; 
NU_FLSx = The estimate of non-unique false localisation site count, based on the ratio of 263 pAla sites from 
51205 alanine amino acids, and the count of each amino acid in the non-unique phosphopeptide PSMs; U_Sx 
= The counts of unique sites observed in the data for each amino acid; CF = The collapse factor estimating 
how the number of false positive sites collapse from the non-unique level to the unique level;  U_FLSx = The 
estimate of unique false localisation sites per amino acid; FLRx = estimate of false localisation rate per 
amino acid; TPSx = The estimate of the count of true positive sites per amino acid. 
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Phosphorylated 
Residue 
pX immonium 
ion m/z 
MS/MS spectra 
No. with a phosphoresidue 
specific immonium ion 
% with a phosphoresidue 
specific immonium ion 
ptmRS ≥ 0.99 ptmRS ≥ 0.75 ptmRS ≥  0.99 ptmRS ≥ 0.75 ptmRS ≥ 0.99 ptmRS ≥ 0.75 
Ser 140.01 3165 12543 9 47 0.3% 0.4% 
Thr 154.03 456 1759 1 3 0.2% 0.2% 
Tyr 216.04 83 399 12 39 14.5% 9.8% 
His 190.04 45 329 0 0 0.0% 0.0% 
Asp 168.01 145 1611 0 12 0.0% 0.7% 
Glu 182.02 153 1722 0 17 0.0% 1.0% 
Lys 181.07 232 844 4 17 1.7% 2.0% 
Arg 209.08 116 567 2 21 1.7% 3.7% 
Cys 155.99 25 126 0 0 0.0% 0.0% 
 
 
Appendix Table S9. Phosphoimmonium ions are not generally indicative of the phosphorylated residue. HCD tandem mass spectra representing unique singly 
phosphorylated peptides, where the site of phosphorylation was localised at either ptmRS > 0.99 or 0.75, were interrogated for residue-specific 
phosphoimmonium ions. Listed are the number and percentage of MS/MS spectra that contain the residue-specific phosphoimmonium ion (>5% relative signal 
intensity). With the exception of pTyr, where the phosphoimmonium ion at m/z 216.04 was observed in up to 14.5% of spectra, the number of spectra with a 
residue-specific phosphoimmonium ion was typically <2%.  
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